Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Israel / NCT07120581
Active, not recruiting Observational

Hyperbaric Oxygen Therapy Used on Severely Injured Healthy Individuals With Fungal Infections

NCT07120581 · tracked via the Priya Life Science Israel tracker
Sponsor
Assaf-Harofeh Medical Center
Phase
Observational
Started
2024-08-04
Last updated
2025-08-13

Condition(s) studied

Invasive Fungal InfectionsHyperbaric Oxygen Therapy

Investigational drug(s) / intervention(s)

Hyperbaric Oxygen Therapy

Hyperbaric Oxygen Therapy: Hyperbaric Oxygen Therapy at increasing pressure to 2.8 ATA for 2 hours sessions. Breaks of 5 every 20 minutes from the oxygen to air to avoid hyperoxia. Continued for the duration of the hospitalization in the ICU on a daily basis.

Study summary

The goal of this observational study is to learn about the effects of Hyperbaric Oxygen Therapy on healthy individual who suffer from invasive fungal infection caused by severe trauma, who do not respond to conventional treatment. The main question it aims to answer is:

Does the treatment aid in eradicating the infection and improve the overall outcome of such patients?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * at least 18 year old * Trauma as the insult type causing the infection * Refractory IFI with failure to respond to standard therapy (medical and surgical) * Hyperbaric Oxygen Therapy as part of the treatment Exclusion Criteria: * Patients who did not recieve hyperbaric oxygen therapy as part of the treatment * Patients with immunosuppression background

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Shamir Medical Center Ẕerifin Israel

More Assaf-Harofeh Medical Center trials in Israel

Colorectal Metastasis Prevention International Trial 2 Recruiting
Cross Modal Correlation of EEG and MRI Functional Connectivity: An Investigative Study Recruiting
Same Day Discharge Vs. Hospitalization for Operative Fixation of Distal Radius Fractures Enrolling by invitation
Tranexamic Acid During Colonic Endoscopic Resection Procedures Recruiting
Operative Hysteroscopy Versus Suction Curettage for Surgical Termination of Early Pregnancy Loss (Miscarriage) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07120581 on ClinicalTrials.gov ↗ ← All trials in Israel